PMC7337599_01
Vaginal ultrasound (A) July 2018 and (B) January 2019. No change was observed in endometrial thickness during ospemifene treatment.
dic-2020-3-6-g001.jpg
PMC7337599_01_dic-2020-3-6-g001.jpg
f1-dic-2020-3-6
VVA was further improved and she expressed a desire to continue treatment. Vaginal ultrasounds performed in July 2018 and January 2019 indicated atrophy of the uterus and ovaries on both occasions and no change in endometrial thickness over this period (Figure 1).
Mammography from (A) December 2017 and (B) January 2019. No change was observed in breast density during ospemifene treatment.
dic-2020-3-6-g002.jpg
PMC7337599_01_dic-2020-3-6-g002.jpg
f2-dic-2020-3-6
Mammography was normal (B1) with no changes since the previous assessment in December 2017 (Figure 2).
PMC7337599_02
Pale epithelium with a cornered appearance in a postmenopausal woman with vulvovaginal atrophy.
dic-2020-3-6-g003.jpg
PMC7337599_02_dic-2020-3-6-g003.jpg
f3-dic-2020-3-6
Physical examination revealed pale and atrophic external genitalia with loss of rugae, friable epithelium, atrophic labia minora, and lipodystrophy of the labia majora (Figure 3).
Observable difference in epithelial color and hydration after 1 month's treatment with ospemifene.
dic-2020-3-6-g004.jpg
PMC7337599_02_dic-2020-3-6-g004.jpg
f4-dic-2020-3-6
On examination, clinical improvement was observed in the patient's vulvar and vaginal epithelium (Figure 4).